JP2003515534A5 - - Google Patents

Download PDF

Info

Publication number
JP2003515534A5
JP2003515534A5 JP2001537928A JP2001537928A JP2003515534A5 JP 2003515534 A5 JP2003515534 A5 JP 2003515534A5 JP 2001537928 A JP2001537928 A JP 2001537928A JP 2001537928 A JP2001537928 A JP 2001537928A JP 2003515534 A5 JP2003515534 A5 JP 2003515534A5
Authority
JP
Japan
Prior art keywords
pentamidine
combination
efficiency
alone
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001537928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003515534A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2000/001355 external-priority patent/WO2001035935A2/en
Publication of JP2003515534A publication Critical patent/JP2003515534A/ja
Publication of JP2003515534A5 publication Critical patent/JP2003515534A5/ja
Pending legal-status Critical Current

Links

JP2001537928A 1999-11-16 2000-11-16 がん治療のためのエンド−エクソヌクレアーゼ活性の阻害剤 Pending JP2003515534A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16568899P 1999-11-16 1999-11-16
US60/165,688 1999-11-16
PCT/CA2000/001355 WO2001035935A2 (en) 1999-11-16 2000-11-16 Inhibitors of endo-exonuclease activity such as pentamidine for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2003515534A JP2003515534A (ja) 2003-05-07
JP2003515534A5 true JP2003515534A5 (enExample) 2007-09-20

Family

ID=22600019

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001537928A Pending JP2003515534A (ja) 1999-11-16 2000-11-16 がん治療のためのエンド−エクソヌクレアーゼ活性の阻害剤

Country Status (12)

Country Link
US (2) US20060276548A1 (enExample)
EP (1) EP1231910B1 (enExample)
JP (1) JP2003515534A (enExample)
AT (1) ATE431734T1 (enExample)
AU (1) AU780538B2 (enExample)
CA (1) CA2388674C (enExample)
CY (1) CY1110503T1 (enExample)
DE (1) DE60042245D1 (enExample)
DK (1) DK1231910T3 (enExample)
ES (1) ES2327313T3 (enExample)
PT (1) PT1231910E (enExample)
WO (1) WO2001035935A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001266838A1 (en) * 2000-06-21 2002-01-02 Georgetown University Inhibitors of matriptase for the treatment of cancer
US6569853B1 (en) 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6693125B2 (en) 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US8053477B2 (en) * 2002-03-29 2011-11-08 University Of Maryland, Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
ITMI20021455A1 (it) * 2002-07-02 2004-01-02 Ugo Raffaello Citernesi Formulazioni fosfolipidiche di lexitropsine loro preparazione ed impiego terapeutico
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
AU2005228410A1 (en) 2004-03-29 2005-10-13 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
WO2006062072A1 (ja) * 2004-12-10 2006-06-15 Tmrc Co., Ltd. 転移癌治療剤および癌転移抑制剤
CA2713428C (en) 2007-12-28 2015-03-31 Server Technology, Inc. Power distribution, management, and monitoring systems and methods
WO2010125462A2 (en) * 2009-05-01 2010-11-04 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
WO2014008592A1 (en) * 2012-07-13 2014-01-16 Oncozyme Pharma Inc. Combinations comprising diamidine compounds and parp inhibitors for use iν treating cancer
WO2019095046A1 (en) 2017-11-16 2019-05-23 Montdorex Inc. Mono- and di-amidine endo-exonuclease inhibitors and methods for inhibiting endo-exonuclease activity
CN115998872B (zh) * 2020-04-15 2025-03-25 四川大学华西第二医院 一种含有抑制核酸内切酶功能的药物及其抗肿瘤的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2145528C3 (de) * 1971-09-11 1981-12-17 Heinrich Mack Nachf., 7918 Illertissen Exonuclease und diese enthaltendes cytostatisches Mittel
EP0585957A1 (en) * 1986-08-06 1994-03-09 Ajinomoto Co., Inc. Recombinant B-cell differentiation factor
JP2770970B2 (ja) * 1987-04-09 1998-07-02 フアイソンズ・ピーエルシー ペンタミジンを含有する医薬組成物
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
US5166140A (en) * 1987-05-05 1992-11-24 City Of Hope Use of certain nucleoside analogs to attenuate cancer cell resistance to DNA damaging chemotherapy
US5585363A (en) * 1987-05-05 1996-12-17 City Of Hope Circumvention of human tumor drug resistance
US4856528A (en) * 1987-06-26 1989-08-15 John Hopkins University Tumor volume determination
US5204352A (en) * 1987-09-29 1993-04-20 The United States Of America As Represented By The Secretary Of The Army Compounds exhibiting anti-parasitic activity and a method for their use
US5084480A (en) * 1987-11-06 1992-01-28 Fujisawa Usa, Inc. Pentamidine salts useful in the treatment of pneumocystis carinii pneumonia
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
MX16687A (es) * 1988-07-07 1994-01-31 Ciba Geigy Ag Compuestos de biarilo y procedimiento para su preparacion.
US5037758A (en) * 1989-01-11 1991-08-06 Her Majesty The Queen In Right Of Canada, As Represented By The National Research Council Of Canada Enhanced production of biosurfactant through the use of a mutated B subtilis strain
GB8903438D0 (en) * 1989-02-15 1989-04-05 May & Baker Ltd New compositions of matter
US5352581A (en) * 1989-03-24 1994-10-04 United States/National Institutes Of Health Sensitive yeast genetic system for identifying agents causing double-stranded DNA damage
AU7162791A (en) * 1989-12-27 1991-07-24 Miroslav Radman Novel system for isolating and producing new genes, gene products and dna sequences
US5489524A (en) * 1991-03-26 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein that has a human Rho motif and deoxyribonuclease activity
US5324830A (en) * 1991-03-26 1994-06-28 United States Of America Chimeric protein that has a human RHo Motif and deoxyribonuclease activity
US5283238A (en) * 1992-04-24 1994-02-01 Immtech International, Inc. Methods of treating cancer using modified C-reactive protein
US5723288A (en) * 1994-05-06 1998-03-03 The University Of North Carolina At Chapel Hill Method of fluorescent detection of nucleic acids and cytoskeleton elements using bis-dicationic aryl furans, and kits useful therefor
US5874283A (en) * 1995-05-30 1999-02-23 John Joseph Harrington Mammalian flap-specific endonuclease
US5643935A (en) * 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
US5916779A (en) * 1995-09-21 1999-06-29 Becton, Dickinson And Company Strand displacement amplification of RNA targets
US5935982A (en) * 1997-02-28 1999-08-10 The University Of North Carolina At Chapel Hill Methods of treating retroviral infection and compounds useful therefor
US5977311A (en) * 1997-09-23 1999-11-02 Curagen Corporation 53BP2 complexes
EP1022286A4 (en) * 1997-10-07 2003-04-09 Ono Pharmaceutical Co POLYPEPTIDES, FOR ENDING CODNA AND THEIR USE
US7115665B1 (en) * 2000-11-16 2006-10-03 Onocozyme Pharma, Inc. Inhibitors of endo-exonuclease activity for treating cancer
CN101532001A (zh) * 2000-03-08 2009-09-16 诺维信公司 具有改变的特性的变体
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US20040010045A1 (en) * 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
US8053477B2 (en) * 2002-03-29 2011-11-08 University Of Maryland, Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same

Similar Documents

Publication Publication Date Title
JP2003515534A5 (enExample)
JP2003520232A5 (enExample)
JP2004500321A5 (enExample)
JP2002536911A5 (enExample)
JP2001522820A5 (enExample)
JP2003520017A5 (enExample)
JPH11204793A5 (enExample)
WO2002018327A3 (en) Guanidinobenzamides as mc4-r agonists
JP2002256889A5 (enExample)
DE60034493D1 (de) Aktualisierung des Headerkompressionszustands in Paketübertragung durch die Nutzung von Bit-stealing
JP2006501124A5 (enExample)
JP2003513115A5 (enExample)
AU2001266575A1 (en) Chemical compounds
JP2008512527A5 (enExample)
PT1360187E (pt) 3,7-diazabiciclo(3.3.0)octanos e a sua utilizacao no tratamento de arritmias cardiacas
NO20031414L (no) Ny oksabispidinforbindelse som er nyttig i behandlingen av hjertearrytmier
JP2000141643A5 (enExample)
USD467463S1 (en) Lid
JP2005536763A5 (enExample)
JP2004517145A5 (enExample)
JP2003529555A5 (enExample)
JP2004526429A5 (enExample)
JPH116484A5 (enExample)
JP2004510103A5 (enExample)
JP2002053774A5 (enExample)